Helix BioPharma Corp.HBP.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · helixbiopharma.com
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company developing novel bio-conjugate drugs targeting cancers that overexpress CEACAM6. Its lead candidate, L-DOS47 (Tumor Defense Breaker™), is an antibody-enzyme conjugate investigated in clinical trials for non-small cell lung cancer, with additional pre-IND pipeline candidates LEUMUNA™ and GEMCEDA™.
Key ratios
ROA
-24.8%TTM
2025
-33.3%2024
-458.7%2023
-166.1%
ROE
-54.7%TTM
2025
-67.2%
Recent news
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Track HBP.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer